Gadisseur A P A, Breukink-Engbers W G M, van der Meer F J M, van den Besselaar A M H, Sturk A, Rosendaal F R
Departments of Hematology/Hemostasis and Thrombosis Research Center, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, the Netherlands..
Arch Intern Med. 2003 Nov 24;163(21):2639-46. doi: 10.1001/archinte.163.21.2639.
Several studies have demonstrated that patient self-management of oral anticoagulant therapy (OAT) can improve treatment quality. However, most of these studies were not conducted within a specialized anticoagulation care system. The objective of the present study was to determine whether patient self-management of OAT improves the quality of care delivered by anticoagulation clinics.
In this randomized study by 2 Dutch anticoagulation clinics 341 patients aged between 18 and 75 years and receiving long-term OAT were divided into 4 groups: an existing routine care group of patients untrained in self-management; a routine care group of trained patients; a group managed weekly at an anticoagulation clinic where international normalized ratios were measured by trained patients; and weekly patient self-management. A 2-step randomization procedure was followed: first, a Zelen-design randomization was performed to distribute patients (without informing them) to the existing care group or to receive training in self-management; second, trained patients were randomized to the 3 other study groups.
Only 25.6% of invited patients agreed to participate in the training program. Patients who remained in the existing care group were within the international normalized ratio target range 63.5% of the time. The type of coumarin taken was a major predicting factor of OAT quality. In all study groups phenprocoumon outperformed acenocoumarol by 11.6% (95% confidence interval [CI], 6.6%-16.5%). Weekly management with phenprocoumon led to a 6.5% improvement (95% CI, 0.0%-13.1%) in time in the international normalized ratio target range when patients were managed at an anticoagulation clinic and to an 8.7% improvement (95% CI, 1.6%-15.9%) when patients were self-managed. Weekly management with acenocoumarol did not improve the quality of OAT.
With selected patients, the quality of OAT obtained through patient self-management is at least as high as that delivered by specialized physicians at anticoagulation clinics. Weekly management of OAT with long-acting phenprocoumon has to be preferred at anticoagulation clinics or, where possible, through patient self-management.
多项研究表明,患者自我管理口服抗凝治疗(OAT)可提高治疗质量。然而,这些研究大多并非在专门的抗凝护理系统内进行。本研究的目的是确定患者自我管理OAT是否能提高抗凝门诊提供的护理质量。
在荷兰两家抗凝门诊进行的这项随机研究中,341名年龄在18至75岁之间且接受长期OAT治疗的患者被分为4组:一组是未接受自我管理培训的现有常规护理患者;一组是接受培训的常规护理患者;一组是在抗凝门诊每周接受管理的患者,其国际标准化比值由接受培训的患者测量;以及每周患者自我管理组。采用两步随机程序:首先,进行Zelen设计随机化,将患者(不告知他们)分配到现有护理组或接受自我管理培训;其次,将接受培训的患者随机分配到其他3个研究组。
只有25.6%的受邀患者同意参加培训项目。留在现有护理组的患者国际标准化比值在目标范围内的时间占63.5%。所服用香豆素的类型是OAT质量的主要预测因素。在所有研究组中,苯丙香豆素的表现优于醋硝香豆素11.6%(95%置信区间[CI],6.6%-16.5%)。当患者在抗凝门诊接受管理时,每周使用苯丙香豆素进行管理使国际标准化比值在目标范围内的时间提高了6.5%(95%CI,0.0%-13.1%),而当患者进行自我管理时提高了8.7%(95%CI,1.6%-15.9%)。每周使用醋硝香豆素进行管理并未提高OAT的质量。
对于选定的患者,通过患者自我管理获得的OAT质量至少与抗凝门诊的专科医生提供的质量一样高。在抗凝门诊或可能的情况下,通过患者自我管理,每周使用长效苯丙香豆素进行OAT管理更为可取。